Clinical Trial Update: Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of alisertib (MLN8237) in ovarian, fallopian tube, or peritoneal cancer following a prior MLN8237 plus paclitaxel Phase 1 study in ovarian …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Alisertib (alisertib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Ovarian Carcinoma, Fallopian Tube Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-06-04